These results support the hypothesis that weakly to moderately recurrent CNVs, either transmitted or occurring , are causing de novo or contributory factors for these diseases. Second, we show that most of these CNVs, which contain genes involved in neurotransmission or synapse formation and maintenance, are present in the 3 pathological conditions, supporting the existence of shared biological pathways between these neurodevelopmental disorders. The development of microarray based technologies for comparative genomic hybridization (array-CGH) analysis has enabled the detection of submicroscopic microdeletions or microduplications also referred as copy number variations (CNVs). In the past months, this approach has been widely used in neurological and psychiatric disorders including mental retardation (MR) , autism spectrum 1 -3 disorders (ASD) and schizophrenia . These studies have suggested that several genes involved in similar neurodevelopmental 4 -7 8 -11
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pathways may be associated with these conditions. However, so far only rare structural variants, sometimes present in a single patient have been identified. It is therefore difficult to decipher which of these variations are causative, which are risk factors and which are only rare polymorphisms unrelated to any pathological phenotype. It is usually considered that rearrangements are likely to be pathogenic, de novo but this argument which is acceptable for rare large rearrangements detectable by conventional cytogenetics, should be considered with caution for smaller CNVs, for which a very high mutation rate is expected. Indeed, it has been estimated that one segmental de novo deletion occurs in one per eight newborns and one segmental duplication in one per 50 newborns, most of these rearrangements being benign polymorphic variants . Therefore, the disease association of CNVs has to be tested systematically by comparing the frequency of 12 each candidate CNV in patients and controls. Given the very low frequency of each CNV, this would require the study of huge series, only achievable in the context of forthcoming meta-analyses. Another problem arises from the fact that the ascertainment of most of the published samples, initially recruited for linkage studies, is biased toward multiplex cases and that control samples, when present, are generally composed of subjects not screened for the studied pathologies. The goal of the present paper was (i) to provide an estimate of the collective frequency of a set of recurrent/overlapping CNVs in three different groups of patients as compared with healthy controls (ii) to assess whether each CNV is present in more than one clinical category.
Material and Methods

Ascertainment and diagnoses
Patients with schizophrenia and subjects with mental retardation were ascertained at Rouen Hospital from consecutive hospitalizations in patients with schizophrenia, or from consecutive referral for phenotypic and genetic investigations in subjects with intellectual disability. The ASD sample included patients ascertained from consecutive consultations in four units specialized in autism diagnosis and evaluation located at Rouen, Dijon, Tours (France) and Messina (Italy) and patients directly referred by the French Autism Foundation. Controls, all ascertained at Rouen, were screened with a standardized data sheet derived from the SADS-LA and were required to be 13 free of any psychotic disorder or MR in themselves or in their first degree relatives. All psychiatric diagnoses were established according to DSM4 criteria following review of case notes and direct examination of subjects. The schedule for affective disorder and schizophrenia A medline search with the words CNV, schizophrenia, autism and mental retardation allowed us to select non exhaustively a set of 28 loci with microrearrangements characterized by prior array-CGH analyses, often in a single patient. This set included major candidate CNV loci identified in ASD and SZ before April 2008 as well as 8 functionally related CNV loci identified in MR ( ). Each locus Table 2 contained generally a single disease-associated CNV, but in some cases overlapping CNVs with different boundaries had been described in patients. The gene content of these loci ranged from 1 to 28. At each locus at least one candidate gene had been previously suggested in the seminal reports and was retained for the present analysis. Functionally, most of these candidate genes can be classified in two main categories related to synapse formation and maintenance or neurotransmission.
Copy number variation at each locus was assessed by quantitative multiplex PCR of short fluorescent fragments (QMPSF), a method based on the simultaneous amplification of several short genomic fragments under quantitative conditions . For each locus, amplicons 17 were designed in the coding sequence of selected candidate genes. All assays were grouped in three multiplex PCR experiments including 10 short genomic fragments (range 101 301bp) each. Primer sequences and PCR conditions are summarized in supplementary Table S1 .
-DNA fragments generated by QMPSF were separated on an ABI Prism 3100 sequencer (Applied Biosystem) and the resulting fluorescence profiles were analyzed using the Gene Scan 3.7 Software (PE Applied Biosystems). For each patient, the QMPSF profile was superimposed to that generated from a reference subject by adjusting to the same level the peak obtained for a control amplicon corresponding to a short exonic fragment of the PBGD gene. When a copy number variation was detected, further analyses aiming to confirm and delineate the size of the rearrangements were performed using additional dedicated QMPSF assays (supplementary figure S1), array-CGH and/or fluorescence in situ hybridization (FISH) analyses.
Agilent 44K array
Oligonucleotide array-CGH was performed using the Agilent Human Genome CGH microarray 4x44K (Agilent Technologies, Santa Clara, CA, USA). This array contains 44 290 60-mer oligonucleotide probes covering the whole genome with an average spatial resolution of 30 35 kb. 84 of the probes reside in intragenic regions, and over 30 000 genes are each represented by at least one probe. All Array-Based CGH for Genomic DNA Analysis ).
"
Fluorescence in situ hybridization (FISH)
FISH analyses were performed on metaphase spreads obtained from peripheral lymphocytes from the patients. Selected Human genomic BAC clones were obtained from the BACPAC resources center ( ). http://bacpac.chori.org
DNA sequencing and paternity checking
Sequence analysis of the coding exons of the gene was performed using primers and PCR conditions previously described PRODH 18 on an Applied Biosystem model 3100 automated sequencer (PE Applied Biosystem). Paternity was checked by microsatellite typing.
Determination of plasma proline level
In patients, plasma proline levels were determined after overnight fasting. All samples were analyzed using ion exchange chromatography on a BIOTRONIK LC 3000 system.
Statistical analysis
Categorical variables were compared by Fisher s exact test. Two hypotheses were tested. First, the distribution of the collective set of ' recurrent/overlapping CNVs found in each group of patients was compared with that found in controls (3 tests). Second, the distribution of each recurrent/overlapping CNV present in our population was compared between each disease group and controls (33 tests). P-values were reported without Bonferroni s correction.
'
Results
CNVs in the control group
Among the 28 loci selected for this study ( ), only one CNV identical to a previously described disease-associated one (i.e. a Table 2 22q11 350kb deletion spanning the and genes) was detected in the control group. This deletion, present in a single PRODH DGCR6 19 control subject, had a low frequency (1/236)similar to that previously reported in Japanese and Canadian populations. A common 20 21 CNV reciprocal to the expected one (i.e. a 350 kb duplication) was also found at the same locus in 6/236 controls. This CNV, also present in 7/236 patients with schizophrenia, 4/260 ASD patients and 9/247 MR patients was clearly a benign polymorphism. Another overlapping reciprocal CNV (i.e. a 490 kb duplication) was detected at the locus located on chromosome 15q13.3. This CNV present in CHRNA7 2/236 controls, 1/236 patients with schizophrenia, 1/260 ASD patients and 1/247 MR was equally unrelated to any pathological condition.
(Supplementary Table S2 )
Diseases associated CNVs
The proportion of recurrent/overlapping CNVs identified among the 28 selected loci in the present sample totaling 743 affected subjects was 11/28 (40 ) . Their collective frequency was 10/236 (4 ) in patients with schizophrenia, 16/260 (6 ) Table 3a association with ASD was reached for the deletion (9/260 in ASD patients vs 1/236 in controls, p 0.02). None of the PRODH/DGCR6 = cases had more than one of these 28 CNVs. Among the four most prevalent CNVs, three, located in 22q11, 16p11 and 15q13, were flanked by known regions of segmental duplication and resulted most likely from a non allelic homologous recombination mechanism (NAHR). At the 2p16 locus, the gene was recurrently disrupted by a set of partially overlapping deletions spanning either the NRXN1 promoter and first exons of neurexin1 alpha or the exons coding for the middle section of this protein as well as for the proximal region of neurexin1 beta. These rearrangements occurred in a region devoid of any segmental duplication and resulted from another mechanism distinct from NAHR.
Transmission and cosegregation in multiplex sibships
Among 27 families in which transmission was tested (69 of the total sample), it was found that only eight CNVs (located in 8p23, % 15q11-q13, 15q13, 16p11 and 22q13) had occurred ( ). Paternal age was not significantly different between families with de novo Table 3a and inherited CNVs (27.2 4.7 y vs 30.7 4.6 y, NS, Mann Whitney U test). In most families, CNVs were transmitted from an de novo ± ± apparently unaffected (although not clinically nor neuropsychologically assessed) parent. This includes a partial duplication of the X linked gene, present in a young male autistic patient, which was inherited from the unaffected mother. reduction of more than 50 of the enzymatic activity is generally required to produce hyperprolinemia . The presence of a mutation
affecting enzyme activity on the second allele is therefore necessary. To examine this issue, the remaining allele was 23 PRODH sequenced in all affected subjects bearing the 350 kb deletion, and, when possible, plasma proline level was assessed. As shown in Table 4 , 14/15 patients harbored a genotype predicted to result in a reduction of at least 70 of enzymatic activity. Among the 10 subjects in % whom plasma proline level was assessed, 7 had mild to severe hyperprolinemia and 3 had plasma proline level at the upper boundary of normal values.
Cosegregation of the CNV with pathological conditions was examined in 4 multiplex families in which DNA from affected siblings was available. In family 144, the two sibs with schizophrenia both harbored the deletion. In family 11695, the two MR PRODH/DGCR6 sibs both harbored the 2p16.3 deletion. In family 14390, the 16p11 deletion was present in the proband with developmental language disorder but not in his mentally retarded sib. In family 33, the 16p11 duplication was present in two sibs with schizophrenia as well as in a non affected sibling, but not in a third sibling with schizophrenia.
Disease specificity
Combining the results of the present study and those of previous reports, we found that, with the possible exception of the maternally derived 15q13 duplication associated with ASD, none of the observed rearrangement was disease-specific. The 22q11 and 2p16 19 1 deletions were found in the three conditions, whereas the 22q13 deletion found in two ASD patients had already been described in ASD and MR , . The 16p11 and 8p23 rearrangements previously described in ASD , , were both found in SZ and also in MR 4 24 -26 4 5 patients for the 16p11 rearrangements. The Xp11.4 duplication spanning the gene, previously described in MR and ASD , , TSPAN7
was found in a patient with SZ, as well as the 17q21 duplication previously described in a patient with MR . Two different sized 15q13 28 duplications encompassing were found in one ASD and one SZ patient. A partial duplication of the 3 gene, encompassing APBA2 GRIA the promoter region and the exons coding for the proximal region of GRIA3 was detected in a single autistic patient. Although slightly different by its size and by the number of duplicated exons, this partial duplication is reminiscent from that recently reported in a patient with MR . At the 8p23 locus, both gain and loss of material were found, as well as at the 16p11 and 17q21 loci, as recently described 29 28
Comorbidity
From a phenotypic point of view, it is noteworthy that 3 out of 9 patients with schizophrenia bearing a candidate CNV had mild MR in an IQ assessment obtained after the onset of their psychotic symptoms ( ). Although postmorbid IQ is likely to constitute an Table 3b underestimate of the premorbid level of cognitive functioning in patients with schizophrenia, cognitive deficits testified by severe learning disorder were already noted in these 3 patients during childhood before the onset of their psychotic symptoms, thus supporting the diagnosis of comorbidity between MR and SZ. With the exception of two subjects who had normal cognitive functioning Arch Gen Psychiatry . Author manuscript Page / Table 3b Comments After a first wave of CNV discovery by array-CGH analyses in neuropsychiatric disorders, this study for the first time examines the involvement of a limited number of candidate loci in large samples of patients with different clinical diagnoses. Two strengths of our study design are the inclusion of controls carefully screened for the studied pathologies and of series of patients mostly ascertained through consecutive admissions or consultations and therefore including subjects belonging either to simplex or multiplex families. Given the expected rarity of each variant, our first goal was not to test the association of every individual CNV with SZ, ASD or MR but to determine whether these variants were collectively more frequent in patients with these diseases than among healthy controls. This aim was successfully achieved and, in addition, we were able to obtain suggestive statistical significance for the association between the 22q11 350 kb deletion and ASD. This deleted segment, located within the chromosomal region deleted in VCFS, a contiguous gene syndrome known to be associated with a high frequency of MR, ASD and psychosis, contained two genes and . Although we PRODH DGCR6
cannot exclude an involvement of in the neuropsychiatric phenotype of the subjects bearing this CNV, previous work from our DGCR6 group strongly suggests that is the prime candidate. We had previously shown that hyperprolinemia, resulting from the partial or PRODH total inactivation of this enzyme (i) may lead to MR and autism in patients with type 1 hyperprolinemia
(ii) is a risk factor for 18 schizoaffective disorder (iii) is inversely correlated with IQ in the VCFS . Here, we show that all but one patients harboring this 32 18 deletion were in fact compound heterozygotes, also bearing mutations affecting enzymatic activity on the second allele. It results in a loss of at least 70 of the predicted PRODH residual activity in 14/15 subjects and in hyperprolinemia in 7/10 assessed subjects.
% Second, we show that both CNVs and CNVs inherited from an apparently healthy parent can be found in patients. For de novo transmitted CNVs, the mode of inheritance of the disease was, in some cases recessive (e.g. hyperprolinemia related to the 22q11 deletion) or implied the transmission of an X linked gene by a woman to her son ( ). Consistent with previous reports , , , the 16p11 GRIA3 4 8 33 rearrangements were inherited from an apparently non affected parent in three families. These CNVs, whose estimated frequency in heterogeneity. This hypothesis, which is not un-plausible for these frequent disorders often characterized by assortative mating, remains speculative since the parents and their relatives were not psychiatrically nor cognitively assessed in these families.
Third and more importantly, our study confirms and extends the conclusions of several recent reports suggesting that a large number of candidate CNVs are not disease-specific but are involved in the expression of different behavioral phenotypes including MR, ASD and SZ. This implies the existence of shared biological pathways between these three neurodevelopmental conditions. These pathways affect chiefly synapse formation and maintenance as well as neurotransmission with a special emphasis on glutamate and GABA. The dysfunction of specific neuronal networks underlying the peculiar symptomatology of each clinical condition most likely depends on additional genetics, epigenetics and environmental factors which remain to be characterized. From a clinical point of view, it should be stressed that despite the diversity of categorical diagnoses, many subjects harboring these CNVs shared some clinical features: 1/3 of patients with schizophrenia and 80 of autistic patients with CNVs had a level of cognitive functioning which falls in the range of mental % retardation. This is in accordance with previous reports showing that that point prevalence of schizophrenia is increased by a factor of 3 in subjects with intellectual disabilities and that 3/4 of autistic patients have mental retardation . However, it should be remembered 34 35 that (i) because attention and communication are markedly impaired in children with autism, assessment of their IQs (even performance IQs in non verbal subjects) are notoriously unreliable and (ii) these results were not obtained in a single community based population, but in three disease groups ascertained according to different schemes, a factor whose exact impact is difficult to appreciate but which is likely to have implications related to the phenotypic severity of these subject.
Finally, we would like to point out the utility of targeted methods for CNV analysis, such as the QMPSF method, as a cost effective alternative to a-CGH for the screening of candidate loci in large case-control cohorts. We plan to conduct extensive resequencing of these candidate genes in order to further validate their role in these conditions.
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: not assessed * deletion also present in a sibling with schizophrenia ** duplication present in a schizophrenic and a healthy sibling, and not present in a schizoaffective sibling *** deletion not present in a sibling with mental retardation **** deletion present in the proband and an affected sibling ¶ maternally derived 
